Clinical trials: Invasive Carcinoma
Non-muscle-invasive Bladder Cancer
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
This is a randomized, open-label, multi-center, global, phase III study to determine the efficacy and safety of Durvalumab + BCG combination therapy in the treatment of patients with non-muscle-invasive bladder cancer
- Trial name
- POTOMAC (NCT03528694)
- Testing
- Durvalumab (MEDI4736), Bacillus Calmette-Guerin (BCG)
- Where
- 120 sites in Australia, Austria and 10 more
- Volunteers
- 1,018 people
- Sponsor
- AstraZeneca
Breast Cancer, Pain
Pain After Tumescent Mastectomy or Standard Mastectomy in Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: New surgery techniques may lessen pain after breast surgery. It is not yet known whether tumescent mastectomy or standard mastectomy results in less pain in women with breast cancer.
- Conditions
- Breast Cancer, Pain, Perioperative/Postoperative Complications
- Trial name
- NCT00859157
- Testing
- therapeutic conventional surgery
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of California, Davis
Newly Diagnosed Operative Invasive Ductal Breast Carcinoma Stage I-II
Vitamin D3 (Vit D3) Supplementation and T Cell Immunomodulation in Patients With Newly Diagnosed Operative Invasive Ductal Breast Carcinoma
This study is for adult females who have been newly diagnosed with breast cancer that includes surgery as part of standard cancer treatment.
- Trial name
- NCT01816555
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Medical University of South Carolina
Non-Muscle Invasive Bladder Neoplasms
Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use
The purpose of this pre-approval access program is to provide access to TAR-200 prior to its marketing authorization for the treatment of participant(s) with high-risk non-muscle invasive bladder cancer (HR-NMIBC).
- Trial name
- NCT06877676
- Testing
- TAR-200
- Sponsor
- Janssen Research & Development, LLC
Bladder Cancer, Cancer of the Bladder, Recurrent
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
Bladder cancer is the most common urinary tract cancer and the 5th most common cancer in the US (1). Yet bladder cancer research is underfunded relative to other common cancers.
- Conditions
- Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
- Trial name
- CISTO (NCT03933826)
- Where
- 36 sites in United States
- Volunteers
- 570 people
- Sponsor
- University of Washington
Non Muscle Invasive Bladder Cancer
The Role of Definitive Radiotherapy in Non Muscle Invasive Bladder Cancer
Bladder cancer is one of the most common malignancies worldwide and represents a major global health burden. According to the GLOBOCAN 2022 estimates, approximately 614,298 new cases and 220,596 deaths from bladder cancer were…
- Trial name
- NCT07873333
- Testing
- Definitive radiotherapy, BCG, Concurrent chemotherapy
- Volunteers
- 70 people
- Sponsor
- Assiut University
Obesity, Weight Loss
Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation
Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor and has a grave prognosis. Obesity is an epidemic in the US.Patients with HCC and obesity are not candidates for liver transplantation, depriving…
- Conditions
- Obesity, Weight Loss, Body Weight, Hepatocellular Carcinoma
- Trial name
- NCT02935478
- Testing
- Embospheres Microspheres
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- St. Louis University
High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study
This is a phase II study to determine the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) which is not…
- Trial name
- NCT05418309
- Testing
- Tislelizumab Nab paclitaxel
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Tianjin Medical University Second Hospital
Breast Adenocarcinoma, Ductal Breast Carcinoma In Situ
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
This phase II trial studies the side effects and how well radiation therapy works in treating patients with stage 0-II breast cancer.
- Conditions
- Breast Adenocarcinoma, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7
- Trial name
- NCT01245712
- Testing
- Accelerated Partial Breast Irradiation, Proton Beam Radiation Therapy, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma
Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis
This is a study to evaluate the primovist as a new contrast agent useful to diagnostic of hepatocellular carcinoma
- Trial name
- PRIGA (NCT01575574)
- Testing
- GADOXETIC ACID
- Where
- Spain
- Volunteers
- 74 people
- Sponsor
- Sara Varea
Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment.
- Conditions
- Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
- Trial name
- NCT04164082
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 390 sites in United States, Guam and 1 more
- Volunteers
- 161 people
- Sponsor
- National Cancer Institute (NCI)
Urinary Bladder Neoplasms
A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
The purpose of this study is to evaluate both the safety and tolerability of up to 4 dosing cycles of TAR-200 for 21 days per dosing cycle in the induction period.
- Trial name
- NCT03404791
- Testing
- TAR-200
- Where
- 12 sites in United States, Spain
- Volunteers
- 35 people
- Sponsor
- Janssen Research & Development, LLC
HCC - Hepatocellular Carcinoma, Cirrhosis
Non-invasive Assessment for Outcome Prediction in Patients With Hepatocellular Carcinoma
This is a single-centre, prospective cohort study. Consecutive patients with compensated liver disease and hepatocellular carcinoma (HCC) for curative-intent treatment will be invited to this study.
- Trial name
- NCT07036874
- Testing
- transient elastography and oesophagogastroduodenoscopy
- Where
- Hong Kong
- Volunteers
- 159 people
- Sponsor
- Chinese University of Hong Kong
Barrett Esophagus
A Minimally-Invasive Sponge on a String Device for Screening for Barrett's Esophagus
This study is being done to collect data on the potential use of a sponge on a string device as a non-invasive tool in evaluating patients with Barrett's Esophagus compared to healthy controls.
- Trial name
- NCT02560623
- Testing
- Biopsy, Biospecimen Collection, Endoscopic Procedure
- Where
- 6 sites in United States
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Bladder Cancer, NMIBC
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior…
- Conditions
- Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma Recurrent
- Trial name
- NCT03914794
- Testing
- Pemigatinib
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
Lifestyle Intervention for High Risk Cancer Survivors
The goal of this behavioral research study is to find out more about the health behaviors of cancer survivors. Researchers want to understand the cultural, social, and environmental factors related to physical activity and…
- Trial name
- NCT01508273
- Testing
- Exercise Program, Website, Exercise DVD
- Where
- 3 sites in United States
- Volunteers
- 1,150 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Breast Carcinoma
Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses
The overall purpose of this study is to assess whether celecoxib can reduce the change in collagen alignment and inflammatory response in the tumor tissue of primary breast cancer patients with invasive breast carcinoma after 2…
- Trial name
- NCT03185871
- Testing
- Celecoxib
- Sponsor
- University of Wisconsin, Madison
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery
This phase II trial studies how well accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy works in treating patients with breast cancer that has not spread beyond the breast or the axillary lymph…
- Conditions
- Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive, Invasive Breast Carcinoma, Progesterone Receptor Positive
- Trial name
- TRIUMPH-T (NCT02526498)
- Testing
- Accelerated Partial Breast Irradiation, High-Dose Rate Brachytherapy, Questionnaire Administration
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Rutgers, The State University of New Jersey
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases).
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT04647916
- Testing
- Sacituzumab Govitecan
- Where
- 296 sites in United States
- Volunteers
- 44 people
- Sponsor
- SWOG Cancer Research Network
Tubular Breast Cancer, Mucinous Breast Cancer
Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer
The investigators hypotheses that paclitaxel combined with cisplatin in a weekly-based regimen as neoadjuvant chemotherapy is effective and tolerable for locally advanced breast cancer.
- Conditions
- Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer, Inflammatory Breast Cancer
- Trial name
- SHPD001 (NCT02199418)
- Testing
- Paclitaxel, Cisplatin
- Where
- 2 sites in China
- Volunteers
- 132 people
- Sponsor
- RenJi Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.